Biotech Values

[DewDiligence]

(SGEN)—MRK presents KEYNOTE-204 data in rrcHL—success on the PFS co-primary endpoint was announced in Mar 2020 without details (#msg-154106381):

https://www.businesswire.com/news/home/20200513005705/en

KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88; p=0.00271]) and showed a median PFS of 13.2 months compared with 8.3 months for patients treated with brentuximab vedotin (BV), a current standard of care in this patient population.

…KEYNOTE-204 serves as the confirmatory trial for the KEYTRUDA accelerated approval hematology indications and the company plans to submit these data to global regulatory authorities this year.

The OS data from this trial are still not mature.